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our institute, from January 1st 2015 to December 31st 2015. Hyperglyce-
miawas diagnosed with a random blood sugar (RBS) level of200mg/dl or
a fasting blood sugar (FBS) value of 126mg/dl. Patients with pre-existing
diabetes were excluded from analysis.
Results: 165 children with newly diagnosed ALL were analysed of which
eight patients (4.8%) were detected to have hyperglycemia (Range 139 e
646mg/dl). Seven of the patients were females and 50% of them were 10
years of age. No patient had pre-existing diabetes. Five patients (62.5%)
required insulin along with metformin to attain adequate glucose control
while two patients were treated with metformin alone. One of the patients
developed hyperglycemia with an RBS of 264while on treatment for septic
shock and expired shortly after. One child presented with ketoacidosis
associated with blood sugar of 554mg/dl and also had pancreatitis. Two
children had a family history of diabetes mellitus.
Conclusion: The occurrence of hyperglycemia in our study was lower than
previously reported in literature. The incidence of hyperglycemia was
signiﬁcantly increased in female children  10 years of age (p¼0.002).LM-1_V1.6
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Introduction: Acute Lymphoblastic Leukemia is hallmarked by hetero-
geneous characteristics and treatment responsiveness in different sub-
types. Although, the overall cure rate of ALL has improved signiﬁcantly
over the past few decades, cure rates for speciﬁc ALL subgroups vary
signiﬁcantly. Age at diagnosis is identiﬁed as an important prognostic
marker of pediatric ALL. This study aims at analyzing clinical, hemato-
logical, biochemical, immunophenotypical parameters and treatment
responsiveness in children upto two years of age, who are diagnosed with
ALL.
Materials & methods: It is a retrospective data analysis conducted at a
Tertiary Care Cancer Centre in South India. The study population includes
all Pediatric ALL upto 2 years of age, registered at this institute during
January 2009 to December 2013. The details included in the study were
collected from case records, hospital cancer registry and during follow up
and percentages were calculated for the variables using appropriate sta-
tistical tools.
Results: The total number of pediatric malignancies registered during the
period were 2640, out of which 422 cases were under 2 years of age with
ALL contributing 122 cases (29%).Among them, 48 children refused treat-
ment due to various reasons and four were lost to follow up. Thus, 70
children are eligible for analysis.
Among 70 children, infants were 13 (18%) and the remaining 57 children
(82%) were in the 1-2 years group. There were 39 males (56%) and 31 fe-
males (44%), the ratio being 1.25:1. Fever was present in 62 children (88%),
and pallor in 57 (81%). Hepatosplenomegaly was observed in 59 children
(84%) and isolated hepatomegaly in 9 (14%). Lymphadenopathy was noted
in 52 (74%).Bleeding manifestations were present in 9 (11.5%) and paroti-
domegaly in 3 (4.25%).
Hemogram revealed hemoglobin <7gm/dL in 25 children (35%), 7-11 gm/
dL in 35 (50%) and >11 in 10 (15%).Initial WBC count was < 10,000 in 25
children (36%), another 36% had counts between 10,000- 49,000 and the
remaining 20 (28%) hadmore than 50000.Platelet count was <20,000 in 14
children (20%), 20,000-99,000 in 51 (74%) and >1 lakh in 6%.
Serum LDH was elevated (>250 IU) in 45 children (64%) and Uric acid in 8
(11.5%).Renomegaly was detected by ultrasound in 12 (17%).Only one child
had CNS 3 disease.L1morphologywas seen in 66 children (94%) and L2 in 4
(6%). Immunophenotype was done in 44 children, 41 (93%) were Precursor
B ALL and 3 (7%) Precursor T ALL.
Event Free Survival was 63%. Among 26 children who succumbed (37%),
three died before the commencement of chemotherapy (4.3%), 6 childrendied during induction (8.5%) and 17 (24.2%) died after relapse. Four out of
11 infants (36%) and 40 among 1-2 years group (70%) survived.
Conclusion: Commonest clinical features were fever, hepatosplenomegaly
and pallor. Predominant morphology was L1 and immunophenotype,
Precursor B ALL. Treatment of infantile ALL is a challenge and is associated
with signiﬁcantly lower survival as compared to 1-2 years group.
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Purpose: To evaluate treatment response, patterns of failure and prog-
nostic factors for patients with NLPHL treated at the Tata Memorial Hos-
pital (TMH).
Materials and Methods: Between January 2008 & July 2013, 62 patients
with histologically proven NLPHL in the age group of 6-70yrs (Median
30.6Yrs) were treated at TMH. Forty ﬁve (73%) were males. Majority had
Stage I (48%) & Stage II (24%) disease. Fifteen (24%) had bulky disease at
presentation. Sixteen (26%) were treated with Involved Field Radiation
Therapy (IFRT) alone, 18 (29%) received Chemotherapy (CTh) alone, while
23 (39%) received a combination of CTh followed by IFRT. Five patients
underwent surgery as the local treatment. The IFRT doses were in the
range of 20-36 Gy. Thirty-four (80%) patients received ABVD CTh. Five (8%)
patients received Rituximab. Primary MINE CTh was used for 4 (6%)
patients.
Results: After a median follow-up of 18 months, the 2 year disease free
survival (DFS) and overall survival (OS) were 86% and 98% respectively.
Complete response (CR) at completion of primary treatment was 94%. At
last follow up 55 (89%) were alive without disease. Two (3%) patients each
had in-ﬁeld, out of ﬁeld and disseminated relapse. Four (6%) had residual
disease and one (2%) had transformation to DLBCL. Six (55%) patients
received salvage treatment (3 IFRT, 3 CTh), of which 4 were disease free at
last FU. On univariate analysis, early stage, absence of B symptoms and use
of IFRT resulted in superior DFS. For patients with early stage disease (stage
I and II), there was no difference in DFS (94%) between patients receiving
IFRT alone and CTh + IFRT. The use of IFRT was associated with improved
DFS (91% vs. 78%, p¼0.57). All patients tolerated treatment well without
any grade III or IV toxicities.
Conclusion: NLPHL is associated with excellent overall survival. For pa-
tients with early stage disease, IFRT alone results in similar outcomes
compared to CTh+IFRT. Early Stage at presentation, absence of B symptoms
and the use of IFRT confers superior outcome.
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POSITIVE ACUTE LYMPHOBLASTIC LEUKAEMIA (PH +VE ALL) USING
AGGRESSIVE CHEMOTHERAPY WITH IMATINIB IN INDIA
Kalasekhar Vijayasekharan, Nirav Thackar, Gaurav Narula, Brijesh
Arora, Nikhil Patkar, Sumit Gujral, Prashant Tembhare, Mani
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Introduction: Ph +ve ALL is a very high-risk subset of childhood ALL with
historically poor outcomes without stem cell transplantation (SCT) before
the advent and use of Imatinib Mesylate. The incidence of Ph +ve ALL at our
centre is higher at 7% as compared to 2-3% in the west. There is a paucity of
data on the clinical presentation outcomes of Ph+ve ALL in India, where
SCT is not affordable for most patients.
Aim: We conducted a retrospective analysis of paediatric Ph +ve ALL pa-
tients treated with intensive chemotherapy with or without Imatinib.
Abstracts / Pediatric Hematology Oncology Journal 1 (2016) S1eS33 S9Materials and methods: We audited records of Ph +ve ALL paediatric
patients diagnosed between January 2005-December 2014 who under-
went treatment with institutional ALL protocol (MCP-841) with or without
Imatinib. No patient underwent SCT. EFS was calculated from date of
diagnosis to date of relapse/progressionwhile OS was calculated from date
of diagnosis to date of last follow up.
Results: A total of 104 patients were diagnosed with Ph+ ALL. The median
age 11 years vs 7.9 years, Male:Female ratio of 4:1 vs 2:1 and median WBC
count 88,000 cells/mm3 vs 40,514 cells/mm3 was higher compared to
west. Similarly CNS involvement: 4 were CNS II (5%) and15 were CNS III
(20%) was higher compared to 6% inwest. Also, 86% children had NCI high-
risk disease compared to 60% inwest. Of 94 patients who started therapy at
our centre, 72 patients received Imatinib during their treatment: 29 during
induction and 43 post-induction. Fourteen did not receive Imatinib and 8
abandoned therapy before response evaluation. Median overall survival
(OS) of the entire cohort was 18 months and estimated 5-year OS and EFS
was 29% and 23% respectively. OS for patients who received Imatinib at any
time during therapy was 38%. However, none of the patients who did not
get Imatinib survived for 3 years. Five-year EFS in patients who received
Imatinib in induction was signiﬁcantly worse at 23% compared to 34% for
those who started it post-induction (p¼0.03). However, there was no
statistical difference in toxic deaths and morphologic remissions between
the groups. The 5-year overall survival of NCI low-risk group 57%
compared to 24% in NCI-high risk group.
Conclusion: Ph+ ALL is more common in India and presents with higher
age and white cell count, as well as high prevalence of CNS involvement
and NCI high-risk disease. Outcome of Ph+ALL without Imatinib and stem
cell transplantation is dismal. Combined therapy including aggressive
chemotherapy and Imatinib improves outcome but outcome of NCI-High
risk disease is suboptimal.
Keywords: Philadelphia-Positive Acute Lymphoblastic Leukemia, Imatinib,
Children
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Background: Majority of mature B-ALL blasts express B lymphocyte an-
tigen (CD20) on their surface however, only 30- 50% of B-cell precursor ALL
blasts express CD20. The incongruous expression of CD20 in BCP-ALL pa-
tients and its prognostic relevance has been reported in adult and pediatric
cases but with discrepant results. In view of this we aimed to determine
the prognostic impact of CD20 expression in pediatric BCP-ALL patients
treated at our department.
Aim of the study: To investigate and correlate the expression proﬁle of
CD20 in precursor B-cell ALL patients with treatment outcome.
Methodology: Mononuclear cells were isolated using ﬁcoll-histopaque
layering technique from bone marrow (BM)/peripheral blood (PB) sam-
ples. Immunophenotyping of blast cells at diagnosis was done by multi-
parametric ﬂow cytometry. Expression of antigens on leukemic cells was
determined by using a 6-dimensional space formed by 2 light scatter pa-
rameters (forward scatter [FSC] and side scatter [SSC]) and 4 ﬂuorescence-
associated characteristics. The existence of blast cell population was
established on the basis of abnormal antigen expression proﬁles of the
blasts as compared to the control.
Results: A total of 65 pediatric patients (median age 9 yrs, range 1-17 yrs;
M: F 4:1; median TLC-17.4x109/l, range 1.1-715x109/l) were studied. CD20
positivity was deﬁned as more than 20% of leukemia blasts expressing
surface CD20. Expression of CD20 was present in 37/65 (57%) patients with
BCP ALL. A worse outcome has been observed in our patients expressing
CD20 than thosewithout the expression. Disease free survival at 20months
in CD20-positive and CD20-negative groups (33% [95% CI, 10-54] versus
89% [95% CI, 54-96], P¼0.002) was statistically signiﬁcant. Overall survival
at 18 months (46% [95% CI, 26-61] versus 65% [95% CI, 40-78], P¼0.01) was
also poorer in CD20-positive group than CD20-negative group.Conclusion: Expression of CD20 on leukemic blasts found to be higher in
our pediatric ALL patients and is associated with poorer outcome as
compared to mostly reported in various studies. This should be explored
further in Indian scenario with regard to prognosis.
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Introduction: Plasmablastic lymphoma is a rare form of non Hodgkin
lymphoma. Little data exists on its epidemiology and outcome in children.
We aimed to study the clinical, epidemiological proﬁle and outcome of
plasmablastic lymphoma in our centre.
Methods and materials: This is a retrospective analysis of 10 years data
from January-2006 to December-2015 at Tata Memorial Centre, Mumbai.
Analysis included all children who presented to our hospital during this
period and diagnosed to have plasmablastic lymphoma by histopathology
and immunohistochemistry. Patients received various multiagent
chemotherapeutic regimens. The outcome of these patients was analyzed.
Results: Thirteen cases of pediatric plasmablastic lymphoma were diag-
nosed and treated in our center during the study period. Elevenwere male
and 2 female. Median age at diagnosis was 12 years (Range1-15 years). HIV
infection was detected in all except 3 children. Four patients had B
symptoms at presentation. Various sites of involvement at diagnosis were
lymph nodes (9 patients), paranasal sinuses (7 patients), bone (4 patients),
pleura (1 patient), orbit (1 patient) and soft tissue (1 patient). Bone
marrow and CSF were involved in 5 and 2 patients respectively, while 2
patients had involvement of both. Patients were given various multi agent
chemotherapeutic regimens like MCP-842, CVEP (Cyclophosphamide,
Vincrstine, Etoposide, Prednisolone), EPOCH (Etoposide, Prednisolone,
Vincristine, Cyclophosphamide, Adriamycin) and oral metronomic
chemotherapy (6-Thioguanine, Etoposide). All patients with HIV infection
also received antiretroviral therapy. At last follow up, 4 patients were
disease free, 6 patients died of disease progression, 1 patient died of cause
unrelated to disease and 2 patients lost to follow up (one patient HIV
positive and one HIV negative).
Conclusion: Plasmablastic lymphoma is an aggressive non Hodgkin lym-
phoma in children. Majority of cases are HIV positive and present with
disseminated disease. The most common sites of involvement include
lymph nodes and paranasal sinuses. Despite intensive chemotherapy
outcome is poor.
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CHILDHOOD ACUTE MYELOID LEUKEMIA: FOLLOW UP EXPERIENCE
OF 2 YEAR COHORT FROM TATA MEDICAL CENTER, KOLKATA
Dipshikha Maiti, Shekhar Krishnan, Anirban Das, Mayur Parihar, Neeraj
Arora, Sanjay Bhattacharya, Arpita Bhattacharyya, Vaskar Saha. Tata
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Background: Acute myeloid leukemia (AML) is a difﬁcult disease to treat
in resource limited settings. Data from India is limited to identify trends/
shortcomings, and plan remedial strategies.
Objective: To analyze the clinical proﬁle and outcome in children with
AML treated with mitoxantrone-based induction protocol.
Method:
Study type: Retrospective observational study.
Study Setting: Undertaken between January 2014 and December 2015 in
Tata Medical Center, Kolkata.
Inclusion criteria: <18-years, presenting with a diagnosis of de novo AML.
Exclusion criteria: Acute promyelocytic leukemia, Down syndrome and
secondary AML.
Classiﬁcation & Stratiﬁcation: Genetic classiﬁcation by a combination of
karyotyping with G banding technique and FISH analysis for t(8;21), inv 16,
t(15;17), MLL gene rearrangements in all children.
Stratiﬁed based on the WHO classiﬁcation to standard, intermediate and
high-risk groups.
